<p>Bengaluru: India’s pharmaceutical market is poised to double, reaching $120 billion by 2030 according to a report by Boston Consulting Group (BCG) and the Organisation of Pharmaceutical Producers of India (OPPI) out on Thursday.</p>.<p>India’s pharma market is currently valued at approximately $60 billion.</p>.<p>By financial year 2026-27 (FY27), the pharma industry is set to grow to $70.3 billion according to a CareEdge Ratings webinar on Thursday, growing by 9 per cent between FY25 and FY27. This will be largely driven by increasing exports to countries like the US, and by new launches by Indian pharma companies. The export to domestic ratio is expected to remain at 51:49.</p>.<p>The projections require the industry to grow by $50 billion in three years, (between 2027 and 2030), and the overall agreement is that Indian pharma industry is looking at a good long-term growth path.</p>.Indian pharma industry set to grow 58% to $130 billion by 2030.<p>Patent expiries will create large opportunities, as per CareEdge. $125 billion worth of total worldwide drug sales are expected to go off patent between 2024 and 2026, opening up $3.5-4 billion market for generic medicine that Indian companies can tap into.</p>.<p>Furthermore, the market share of contract development and manufacturing organisations is expected to improve from $5-8 billion in FY24 to $7-13 billion by FY27 with a compound annual growth rate (CAGR) between 13 per cent and 18 per cent. The growth will be supported by India’s infrastructure and it having the highest USFDA plants outside the US.</p>.<p>Still, high reliance on China for pharma imports was flagged as a continuing concern, with 69 per cent of bulk drugs imported from that country in value in FY25.</p>
<p>Bengaluru: India’s pharmaceutical market is poised to double, reaching $120 billion by 2030 according to a report by Boston Consulting Group (BCG) and the Organisation of Pharmaceutical Producers of India (OPPI) out on Thursday.</p>.<p>India’s pharma market is currently valued at approximately $60 billion.</p>.<p>By financial year 2026-27 (FY27), the pharma industry is set to grow to $70.3 billion according to a CareEdge Ratings webinar on Thursday, growing by 9 per cent between FY25 and FY27. This will be largely driven by increasing exports to countries like the US, and by new launches by Indian pharma companies. The export to domestic ratio is expected to remain at 51:49.</p>.<p>The projections require the industry to grow by $50 billion in three years, (between 2027 and 2030), and the overall agreement is that Indian pharma industry is looking at a good long-term growth path.</p>.Indian pharma industry set to grow 58% to $130 billion by 2030.<p>Patent expiries will create large opportunities, as per CareEdge. $125 billion worth of total worldwide drug sales are expected to go off patent between 2024 and 2026, opening up $3.5-4 billion market for generic medicine that Indian companies can tap into.</p>.<p>Furthermore, the market share of contract development and manufacturing organisations is expected to improve from $5-8 billion in FY24 to $7-13 billion by FY27 with a compound annual growth rate (CAGR) between 13 per cent and 18 per cent. The growth will be supported by India’s infrastructure and it having the highest USFDA plants outside the US.</p>.<p>Still, high reliance on China for pharma imports was flagged as a continuing concern, with 69 per cent of bulk drugs imported from that country in value in FY25.</p>